Vasopeptidases are enzymes responsible for the generation or inactivation of vasoactive peptides. As such, vasopeptidase inhibition represents a significant approach for the treatment of cardiovascular disease. For example, angiotensin-converting enzyme (ACE) inhibitors are FDA approved and widely used to treat hypertension and heart failure. In addition, inhibitors of two other vasopeptidases, neprilysin (NEP) and endothelin-converting enzyme (ECE), are currently in preclinical and clinical development as are combined inhibitors of these enzymes. Recently, considerable data has emerged indicating a role for the vasopeptidases ECE and NEP, and perhaps also ACE, in the degradation of the Alzheimer's amyloid beta-peptide (ABeta). As the abnormal accumulation of ABeta plays a pivotal role in AD pathogenesis, pharmacological inhibition of these vasopeptidases is of considerable concern as they may increase ABeta levels in a manner that increases risk of developing Alzheimer's disease. In this application we propose to directly evaluate the hypothesis that chronic reductions in ECE, NEP, and ACE will result in enhanced ABeta accumulation and AD-like pathology by examining the effects of mice genetically deficient in these enzymes and mice treated with clinically relevant vasopeptidase inhibitors. The results of these studies will further our understanding of the role of NEP, ECE, and ACE in determining ABeta concentration in the brain, while helping to assess the potential risk of the clinical use of vasopeptidase inhibitors. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS048554-03
Application #
7051392
Study Section
Special Emphasis Panel (ZRG1-CDIN (01))
Program Officer
Murphy, Diane
Project Start
2004-04-01
Project End
2009-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
3
Fiscal Year
2006
Total Cost
$278,206
Indirect Cost
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Pacheco-Quinto, Javier; Herdt, Aimee; Eckman, Christopher B et al. (2013) Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J Alzheimers Dis 33 Suppl 1:S101-10
Hanna, A; Horne, P; Yager, D et al. (2009) Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice. Genes Brain Behav 8:676-84
Eckman, Christopher B; Eckman, Elizabeth A (2007) An update on the amyloid hypothesis. Neurol Clin 25:669-82, vi
Parkin, Edward T; Watt, Nicole T; Hussain, Ishrut et al. (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 104:11062-7
Eckman, Elizabeth A; Adams, Stephanie K; Troendle, Frederick J et al. (2006) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281:30471-8
Eckman, E A; Eckman, C B (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33:1101-5
Brown 3rd, James; Theisler, Catherine; Silberman, Simone et al. (2004) Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 279:34674-81